ALEXION Pharmaceuticals has
announced that the US Food and
Drug Administration (FDA) has
granted orphan drug designation
to Soliris (eculizumab) for the
treatment of patients with
myasthenia gravis (MG), a rare,
debilitating neurologic disorder.
Soliris is a first-in-class
terminal complement inhibitor
and is currently approved
for the treatment of patients
with paroxysmal nocturnal
hemoglobinuria and atypical
hemolytic uremic syndrome but
not approved anywhere else in the
world for MG, said the company.The above article was sent to subscribers in Pharmacy Daily's issue from 20 Jun 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 20 Jun 14
NEW data from the Australian Institute of Health and Welfare has revealed around 43% (or 8.5 million) of Australians aged 16-85 have experienced a mental disorder at some point in their lives.
THE Pharmacy Guild of Australia has formally expressed its concerns regarding the potential merger between Sigma and Chemist Warehouse (PD 07 Dec 2023) to the Australian Competition and Consumer Commission (ACCC).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.